Yahoo
LSE - Delayed Quote GBp

Nuformix plc (NFX.L)

0.1050 0.0000 (0.00%)
At close: October 30 at 4:02:21 PM GMT
Chart Range Bar
Loading chart for NFX.L
  • Previous Close 0.1050
  • Open 0.1100
  • Bid 0.1000 x --
  • Ask 0.1100 x --
  • Day's Range 0.1000 - 0.1100
  • 52 Week Range 0.0940 - 0.5550
  • Volume 3,686,105
  • Avg. Volume 22,705,343
  • Market Cap (intraday) 2.74M
  • Beta (5Y Monthly) 1.55
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.

www.nuformix.com

3

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

NFX.L
58.82%
FTSE 100 (^FTSE)
8.04%

1-Year Return

NFX.L
72.37%
FTSE 100 (^FTSE)
9.94%

3-Year Return

NFX.L
63.16%
FTSE 100 (^FTSE)
46.43%

5-Year Return

NFX.L
91.76%
FTSE 100 (^FTSE)
48.25%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.17%

  • Return on Equity (ttm)

    -50.94%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -622.5k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    930.28k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -390.46k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: